Document Detail


Tuberculous and non-tuberculous granulomatous lymphadenitis in patients receiving imatinib mesylate (glivec) for metastatic gastrointestinal stromal tumor.
MedLine Citation:
PMID:  23569448     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Imatinib mesylate (IM) is the standard treatment for BCR-ABL-positive chronic myelogenous leukemia (CML) and is the first-line adjuvant and palliative treatment for metastatic and inoperable gastrointestinal stromal tumor (GIST). IM is not known to be associated with an increased risk for development of granulomatous diseases.
METHODS: We describe our experience with 2 patients (42 and 62 years of age) who developed granulomatous disease during IM treatment for metastatic GIST.
RESULTS: Mean duration of IM treatment was 12 (range 8-16) months. Enlarged lymph nodes with increased metabolism on FDG-PET-CT examination were detected and resected. Affected sites were supraclavicular (1) and subcarinal/mediastinal (1) lymph nodes. Histological examination revealed caseating and non-caseating granulomas suggestive of tuberculosis and sarcoidosis, respectively. Mycobacterium tuberculosis was detected by PCR in lymph nodes of 1 patient who was then successfully treated by anti-tuberculous agents. The other patient had negative sputum test for acid-fast bacilli and PCR-DNA-analysis was negative for M. tuberculosis and other mycobacteria. He received no anti-tuberculous therapy and had no evidence of progressive lymphadenopathy or new lung lesions during follow-up.
CONCLUSION: Our observations underline the necessity to obtain biopsy material from enlarged or metabolically active lymph nodes developing during IM treatment for timely diagnosis and appropriate treatment of these rare complications. Follow-up without treatment is safe for patients without detectable microorganisms by sputum examination and PCR.
Authors:
Abbas Agaimy; Valeska Brueckl; Daniela Schmidt; Stephanie Krieg; Evelyn Ullrich; Norbert Meidenbauer
Related Documents :
24861428 - Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central...
24505298 - [(18)f]fdg positron emission tomography within two weeks of starting erlotinib therapy ...
24281768 - Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatm...
24154408 - A chest wall mass in small cell lung carcinoma - a second chance at diagnosis.
9264578 - Phase i/ii study of intraperitoneal floxuridine and platinums (cisplatin and/or carbopl...
16575538 - Predicting which children are at risk for ependymoma relapse.
Publication Detail:
Type:  Journal Article     Date:  2013-03-05
Journal Detail:
Title:  Case reports in oncology     Volume:  6     ISSN:  1662-6575     ISO Abbreviation:  Case Rep Oncol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-04-09     Completed Date:  2013-04-10     Revised Date:  2013-04-11    
Medline Journal Info:
Nlm Unique ID:  101517601     Medline TA:  Case Rep Oncol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  134-42     Citation Subset:  -    
Affiliation:
Institute of Pathology, University Hospital, Erlangen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dramatic and delayed response to Doxorubicin-dacarbazine chemotherapy of a giant desmoid tumor: case...
Next Document:  A Successfully Resected Case of Recurrent Lung and Liver Metastases of Rectal Cancer Treated with XE...